Is Sun wooing Lizhu for a larger presence in China?
This article was originally published in Scrip
Executive Summary
Even as Sun Pharmaceutical Industries assimilates Takeda-owned URL's generic business (scripintelligence.com, 18 December 2012), there is speculation that the Indian firm may also be keen to build up its branded generics business in China, possibly via an alliance or even a partial acquisition.
You may also be interested in...
China Beckons: Sun Joins Indian Firms Priming For Larger Presence
Evolving regulations and emerging opportunities appear to have put China firmly on the radar of several frontline Indian firms. Sun Pharma is the latest to join those seeking a larger play in the Asian market.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.